Guardant Health, Inc. - Common Stock (NQ:GH)

179.03 +0.67 (+0.38%)

Delayed Quote Updated: 12:11 PM EDT, Oct 1, 2026 Add to My Watchlist

Price and Volume

Volume	622,375
Open	177.17
Bid (Size)	178.60 (400)
Ask (Size)	179.05 (100)
Prev. Close	178.36
Today's Range	175.49 - 180.91
52wk Range	60.45 - 183.51
Shares Outstanding	101,298,669
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

1 Mid-Cap Stock for Long-Term Investors and 2 We Ignore

September 29, 2026

Mid-cap stocks often strike the right balance between having proven business models and market opportunities that can support $100 billion corporations. Howe...

Via StockStory

September 21, 2026

When Wall Street turns bearish on a stock, it’s worth paying attention. These calls stand out because analysts rarely issue grim ratings on companies for fea...

Via StockStory

Performance

YTD	+76.0%	+76.0%
1 Month	+12.6%	+12.6%
3 Month	+4.8%	+4.8%
6 Month	+96.4%	+96.4%
1 Year	+186.5%	+186.5%

More News

Testing & Diagnostics Services Stocks Q2 Results: Benchmarking Guardant Health (NASDAQ:GH)

September 15, 2026

Via StockStory

Guardant Health’s Shield Blood Test Covered by EviCore by Evernorth for Colorectal Cancer Screening

September 14, 2026

From Guardant Health, Inc.

Via Business Wire

Guardant Health (NASDAQ:GH) Shares Surge After Q2 Revenue Beat and Raised 2026 Outlook ↗

July 30, 2026

Via Chartmill

Guardant Health and Collaborators to Present 20 Abstracts Highlighting Portfolio of Liquid Biopsy Tests for Early Detection and Ongoing Treatment Management at 2026 World Conference on Lung Cancer

September 09, 2026

From Guardant Health, Inc.

Via Business Wire

Business Insider Names Guardant Health One of America's Most Innovative Businesses

September 08, 2026

From Guardant Health, Inc.

Via Business Wire

1 Growth Stock to Add to Your Roster and 2 We Turn Down

September 08, 2026

Via StockStory

Guardant Health Announces Landmark FDA Approval of Guardant360® CDx as Companion Diagnostic for AstraZeneca’s ETCAMAH™ (camizestrant) in Advanced Breast Cancer

September 04, 2026

From Guardant Health, Inc.

Via Business Wire

Guardant Health’s Shield Blood Test Covered by Carelon Health Services for Colorectal Cancer Screening

September 01, 2026

From Guardant Health, Inc.

Via Business Wire

Why Rule Breakers Buy a Stock That's Already "Won" ↗

August 31, 2026

Via The Motley Fool

Guardant Health to Appeal Federal District Court Judgment

August 24, 2026

From Guardant Health, Inc.

Via Business Wire

Guardant Health Sees Shield, MRD and Oncology Testing Growth Accelerate ↗

August 14, 2026

Via MarketBeat

Executive Dumps Over 14,000 Shares of Biotech Stock, Valued at $2.3 Million ↗

August 12, 2026

Via The Motley Fool

Guardant Health Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

August 10, 2026

From Guardant Health, Inc.

Via Business Wire

Guardant Health (GH) Q2 2026 Earnings Call Transcript ↗

August 07, 2026

Via The Motley Fool

2 Cash-Burning Stocks to Target This Week and 1 We Find Risky

August 03, 2026

Via StockStory

GH Q2 Deep Dive: Shield Coverage and Oncology Uptake Drive Strong Revenue Growth

August 01, 2026

Via StockStory

Guardant Health Q2 Earnings Call Highlights ↗

July 31, 2026

Via MarketBeat

Guardant Health (NASDAQ:GH) Delivers Strong Q2 CY2026 Numbers, Stock Soars

July 30, 2026

Via StockStory

Guardant Health Reports Second Quarter 2026 Financial Results and Increases 2026 Revenue Guidance

July 30, 2026

From Guardant Health, Inc.

Via Business Wire

Guardant Health to Participate in Upcoming Investor Conferences

July 29, 2026

From Guardant Health, Inc.

Via Business Wire

Guardant Health (GH) Q2 Earnings Report Preview: What To Look For

July 28, 2026

Via StockStory

Actor and Cancer Advocate Patrick Dempsey Stars in Emotional Tribute Video From Guardant Health Memorializing Those Who Have Lost Their Lives to Colorectal Cancer

July 28, 2026

From Guardant Health, Inc.

Via Business Wire

Guardant Health to Report Second Quarter 2026 Financial Results on July 30, 2026

July 09, 2026

From Guardant Health, Inc.

Via Business Wire

Frequently Asked Questions

Is Guardant Health, Inc. - Common Stock publicly traded?

Yes, Guardant Health, Inc. - Common Stock is publicly traded.

What exchange does Guardant Health, Inc. - Common Stock trade on?

Guardant Health, Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for Guardant Health, Inc. - Common Stock?

The ticker symbol for Guardant Health, Inc. - Common Stock is GH on the Nasdaq Stock Market

What is the current price of Guardant Health, Inc. - Common Stock?

The current price of Guardant Health, Inc. - Common Stock is 179.03

When was Guardant Health, Inc. - Common Stock last traded?

The last trade of Guardant Health, Inc. - Common Stock was at 10/01/26 12:11 PM ET

What is the market capitalization of Guardant Health, Inc. - Common Stock?

The market capitalization of Guardant Health, Inc. - Common Stock is 18.14B

How many shares of Guardant Health, Inc. - Common Stock are outstanding?

Guardant Health, Inc. - Common Stock has 18B shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.